Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rasdegafusp alfa - Celldex Therapeutics Inc

Next Previous
Drug Profile

Rasdegafusp alfa - Celldex Therapeutics Inc

Alternative Names: CDX-1401; DEC-205/NY-ESO-1 vaccine - Celldex; Rasdegafusp alfa

Latest Information Update: 29 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Celldex Therapeutics Inc; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; DEC-205 receptor agonists; Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Fallopian tube cancer; Gynaecological cancer; Malignant melanoma; Myelodysplastic syndromes; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 09 Dec 2023 The efficacy data from a phase I trial in Myelodysplastic syndromes presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 25 Aug 2021 Roswell Park Cancer Institute and Celldex Therapeutics completes a phase I trial in Acute myeloid leukaemia, Chronic myelomonocytic leukaemia, Myelodysplastic syndromes (Combination therapy) in USA (NCT03358719)
  • 18 May 2018 National Cancer Institute completes a phase II trial in Malignant melanoma in USA (NCT02129075)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top